|
|
|
MIRA INFORM REPORT
|
Report No. : |
512310 |
|
Report Date : |
30.05.2018 |
IDENTIFICATION DETAILS
|
Name : |
CENTRAL PHARMA |
|
|
|
|
Registered Office : |
Caxton Road Elm Farm Industrial Estate
MK41 0XZ Bedford |
|
|
|
|
Country : |
United Kingdom |
|
|
|
|
Date of Incorporation : |
2017 |
|
|
|
|
Legal Form : |
Unincorporated company |
|
|
|
|
Line of Business : |
Subject is engaged in Wholesale of pharmaceutical goods |
|
|
|
|
No. of Employees : |
150 |
RATING & COMMENTS
(Mira Inform has adopted New Rating mechanism w.e.f. 23rd
January 2017)
|
MIRA’s Rating : |
NB |
|
Credit Rating |
Explanation |
Rating Comments |
|
NB |
New Business |
No recommendation can be done due to
business in infancy stage |
|
Status : |
New Business |
|
|
|
|
Payment Behaviour : |
Unknown |
|
|
|
|
Litigation : |
Clear |
NOTES :
Any query related to this report can be made
on e-mail : infodept@mirainform.com
while quoting report number, name and date.
ECGC Country Risk Classification List
|
Country Name |
Previous Rating (30.09.2017) |
Current Rating (31.12.2017) |
|
United Kingdom |
A1 |
A1 |
|
Risk Category |
ECGC
Classification |
|
Insignificant |
A1 |
|
Low Risk |
A2 |
|
Moderately Low Risk |
B1 |
|
Moderate Risk |
B2 |
|
Moderately High Risk |
C1 |
|
High Risk |
C2 |
|
Very High Risk |
D |
UNITED KINGDOM - ECONOMIC OVERVIEW
The UK, a leading trading power and financial center, is the third largest economy in Europe after Germany and France. Agriculture is intensive, highly mechanized, and efficient by European standards, producing about 60% of food needs with less than 2% of the labor force. The UK has large coal, natural gas, and oil resources, but its oil and natural gas reserves are declining; the UK has been a net importer of energy since 2005. Services, particularly banking, insurance, and business services, are key drivers of British GDP growth. Manufacturing, meanwhile, has declined in importance but still accounts for about 10% of economic output.
In 2008, the global financial crisis hit the economy particularly hard, due to the importance of its financial sector. Falling home prices, high consumer debt, and the global economic slowdown compounded the UK’s economic problems, pushing the economy into recession in the latter half of 2008 and prompting the then BROWN (Labour) government to implement a number of measures to stimulate the economy and stabilize the financial markets. Facing burgeoning public deficits and debt levels, in 2010 the then CAMERON-led coalition government (between Conservatives and Liberal Democrats) initiated an austerity program, which has continued under the Conservative government. However, the deficit still remains one of the highest in the G7, standing at 3.6% of GDP as of 2017, and the UK has pledged to lower its corporation tax from 20% to 17% by 2020. The UK had a debt burden of 90.4% GDP at the end of 2017.
The UK’s economy has begun to slow since the referendum vote to leave the EU in June 2016. A sustained depreciation of the British pound has increased consumer and producer prices, weighing on consumer spending without spurring a meaningful increase in exports. The UK has an extensive trade relationship with other EU members through its single market membership and economic observers have warned the exit will jeopardize its position as the central location for European financial services. Prime Minister MAY is seeking a new “deep and special” trade relationship with the EU following the UK’s exit. However, economists doubt that the UK will be able to preserve the benefits of EU membership without the obligations.
|
Source
: CIA |
Company
name and Summary
|
Company
name |
Central
Pharma |
|
Operative
address |
Caxton
Road Elm Farm Industrial Estate |
|
Status |
Active |
|
Legal
form |
Unincorporated
company |
Contact
information
|
Company
name |
Central
Pharma |
|
Operative
address |
Caxton
Road Elm Farm Industrial Estate |
|
Correspondence
address |
Caxton
Road Elm Farm Industrial Estate |
|
Telephone
number |
+44
1234 272252 |
|
Email
address |
info@central-pharma.com |
|
Website |
www.central-pharma.com |
Registration
|
Registration
number |
|
|
Status |
Active |
|
Legal
form |
Unincorporated
company |
Activities
|
NACE |
4646:
Wholesale of pharmaceutical goods |
|
Goal |
Pharmaceutical
Suppliers and Wholesalers |
Management
|
Management |
Fullname:
Ms Amanda Bentley |
|
|
|
Employees
|
Year |
2017 |
||||
|
Annual |
150 |
Payments
|
Description |
Due
to the recent establishment there are no payment transactions known. |
The
above data is an indication of the average payment behaviour of the client. the
payment experieneces can be affected by disputes, payment arrangements, etc.
Financial
analysis
|
Trend |
Can
not be evaluated because of the recent establishment of the company |
|
Profitability |
Can
not be evaluated |
|
Solvability |
Can
not be evaluated |
|
Liquidity |
Sufficient |
|
Show
amount in |
Euro |
Key
figures
|
Year |
2017 |
||||
|
Turnover |
45.197.595 |
Financial
statement
|
Last
annual account |
2017 |
|
Remark
annual account |
There
is no financial data published |
|
Type
of annual account |
Corporate |
|
Annual
account |
Central
Pharma |
Profit
and loss
|
Year |
2017 |
||||
|
Net
turnover |
45.197.595 |
Country
information
|
Population |
65.6
million |
|
GDP
per capita |
40.050
USD |
|
Country
risk |
Low |
|
Company
risk |
Very
Low |
Publications
|
Remarks |
Status:
Active |
FOREIGN EXCHANGE RATES
|
Currency |
Unit
|
Indian Rupees |
|
US Dollar |
1 |
INR 67.63 |
|
|
1 |
INR 89.70 |
|
Euro |
1 |
INR 78.20 |
|
GBP |
1 |
INR 89.72 |
Note :
Above are approximate rates obtained from sources believed to be correct
INFORMATION DETAILS
|
Analysis Done by
: |
PRI |
|
|
|
|
Report Prepared
by : |
DNS |
RATING EXPLANATIONS
|
Credit Rating |
Explanation |
Rating Comments |
|
A++ |
Minimum Risk |
Business dealings permissible with minimum
risk of default |
|
A+ |
Low Risk |
Business dealings permissible with low
risk of default |
|
A |
Acceptable Risk |
Business dealings permissible with moderate
risk of default |
|
B |
Medium Risk |
Business dealings permissible on a regular
monitoring basis |
|
C |
Medium High Risk |
Business dealings permissible preferably
on secured basis |
|
D |
High Risk |
Business dealing not recommended or on secured
terms only |
|
NB |
New Business |
No recommendation can be done due to
business in infancy stage |
|
NT |
No Trace |
No recommendation can be done as the
business is not traceable |
NB is stated where there is insufficient information to facilitate rating. However, it is not to be considered as unfavourable.
This score serves as a reference to assess
SC’s credit risk and to set the amount of credit to be extended. It is
calculated from a composite of weighted scores obtained from each of the major
sections of this report. The assessed factors are as follows:
·
Financial
condition covering various ratios
·
Company
background and operations size
·
Promoters
/ Management background
·
Payment
record
·
Litigation
against the subject
·
Industry
scenario / competitor analysis
·
Supplier
/ Customer / Banker review (wherever available)
This report is issued at
your request without any risk and responsibility on the part of MIRA INFORM
PRIVATE LIMITED (MIPL) or its officials.